PropertyValue
?:abstract
  • The serological responses to both SARS-CoV-1 and SARS-CoV-2 virus have some unique characteristics that suggest cross-reactive priming by other human coronaviruses (hCoVs). The early kinetics and magnitude of these responses are, in some cases, associated with worse clinical outcomes in SARS and COVID-19. Cross-reactive hCoV antibody responses have been detected in both SARS and COVID-19 patients. There is also evidence that pre-existing T cell immunity to common cold coronaviruses can prime the response to SARS-CoV-2. Studies in non-human primates show that SARS-CoV-1 S-protein vaccine-induced antibodies are associated with acute lung injury in macaques challenged with SARS-CoV-1. Here we discuss the potential of cross-reactive immunity to drive the immunopathogenesis of COVID-19 and its implications for current efforts to develop immune-based therapies and vaccines.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2020.567710
?:journal
  • Front_Immunol
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/141dfcdd312f451b33e8c88ddaa307f9c156756c.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7594548.xml.json
?:pmcid
?:pmid
?:pmid
  • 33178193.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Is Cross-Reactive Immunity Triggering COVID-19 Immunopathogenesis?
?:type
?:year
  • 2020-10-15

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/hmtrlrng>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/hmtrlrng>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all